filgrastim
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Normal PBPC Donors
Conditions
Normal PBPC Donors
Trial Timeline
Nov 1, 2003 → Sep 1, 2007
NCT ID
NCT00115128About filgrastim
filgrastim is a pre-clinical stage product being developed by Amgen for Normal PBPC Donors. The current trial status is completed. This product is registered under clinical trial identifier NCT00115128. Target conditions include Normal PBPC Donors.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002126 | Phase 2 | Completed |
| NCT00115128 | Pre-clinical | Completed |
| NCT00501228 | Pre-clinical | Terminated |
Competing Products
20 competing products in Normal PBPC Donors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Roxadustat | Astellas Pharma | Phase 1 | 33 |
| Donepezil | Eisai | Approved | 85 |
| eribulin mesylate | Eisai | Phase 2 | 52 |
| Lurasidone HCl | Sumitomo Pharma | Phase 1 | 33 |
| Eybelis ophthalmic solution 0.002% | Santen Pharmaceutical | Approved | 85 |
| Triptorelin | Merck | Pre-clinical | 23 |
| Temozolomide + Vorinostat | Merck | Phase 2 | 52 |
| LDE225 | Novartis | Phase 1 | 33 |
| LDK378 | Novartis | Phase 1 | 33 |
| cyclosporine micro-emulsion | Novartis | Approved | 85 |
| LDK378 | Novartis | Phase 1 | 33 |
| LEE011 | Novartis | Phase 1 | 33 |
| LEE011 | Novartis | Phase 1 | 33 |
| mycophenolate mofetil | Roche | Phase 1 | 33 |
| PF-06423264 | Pfizer | Phase 1 | 32 |
| PF-05221304 | Pfizer | Phase 1 | 32 |
| BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose Solution | Bristol Myers Squibb | Phase 1 | 32 |
| tolebrutinib | Sanofi | Phase 1 | 32 |
| Venglustat (GZ402671) | Sanofi | Phase 1 | 32 |
| Rilzabrutinib | Sanofi | Phase 1 | 32 |